Some Details About Google Related Genome Start-up, 23andMe

12 thoughts on “Some Details About Google Related Genome Start-up, 23andMe”

  1. 23andme is not the only company is this space. Navigenics has been far less cagey about what they are going to be offering. Their offerings are llong the same lines with genotyping services/instrumentation coming from Affymetrix.

    Just genotyping individuals is just the start. It will be very interesting to see how this field ends up being regulated.

  2. I am sort of getting belatedly informed on the controversial deal. Disclosure is one thing, transparency is another. Why is there no transparency about this deal? Surely a why statement was in order, given the peculiar details. Conflicts of interest are not avoided by disclosures, but by transparency…and this does not require details of the business. A mere mention of the strategic aim should be enough. Has that been done? I would even argue that by “disclosing” the Google pedigree of the deal, a higher valuation may be rigged up from investors in a Series B/Second round or whatever you call it in the Valley! In which case, disclosure in this case in itself constitutes a dubious act.

  3. I wonder how they are going to manage the load of such requests coming in?

    I wonder whether it is paid or free service?

    I also wonder what they are going to do with this information later on… So they collected 500,000 reports – which they are going to keep behind closed password-protected doors? Having Google mentality (and Google direct interest in the company), should they make all this information searchable and public? How are they going to deal with privacy issues then?

    Imagine a young couple dating and one of them checking the site for other’s half genetical retardation diseases… That would make relationship so much fun!

This site uses Akismet to reduce spam. Learn how your comment data is processed.